EORTC Bladder Cancer Predictor
Recurrence and progression risk assessment
Enter the six clinical and pathological factors to estimate 1-year and 5-year risks.
About the EORTC risk tables
The EORTC 2006 model estimates recurrence and progression after transurethral resection in patients with non-muscle-invasive Ta/T1 bladder cancer. It was derived from 2,596 patients enrolled in seven EORTC trials and uses six clinical and pathological factors.
The model uses tumor number, tumor size, prior recurrence rate, T category, concomitant carcinoma in situ, and tumor grade according to the 1973 WHO classification. It reports separate point totals and risk estimates for recurrence and progression.
Point allocation used by this calculator
| Factor | Category | Recurrence | Progression |
|---|---|---|---|
| Number of tumors | Single | 0 | 0 |
| 2–7 | 3 | 3 | |
| 8 or more | 6 | 3 | |
| Tumor diameter | Less than 3 cm | 0 | 0 |
| 3 cm or greater | 3 | 3 | |
| Prior recurrence rate | Primary | 0 | 0 |
| One or fewer per year | 2 | 2 | |
| More than one per year | 4 | 2 | |
| T category | Ta | 0 | 0 |
| T1 | 1 | 4 | |
| Concomitant CIS | No | 0 | 0 |
| Yes | 1 | 6 | |
| WHO 1973 grade | G1 | 0 | 0 |
| G2 | 1 | 0 | |
| G3 | 2 | 5 |
Risk bands and estimated probabilities
| Outcome | Points | 1 year | 5 years |
|---|---|---|---|
| Recurrence | 0 | 15% | 31% |
| Recurrence | 1–4 | 24% | 46% |
| Recurrence | 5–9 | 38% | 62% |
| Recurrence | 10–17 | 61% | 78% |
| Progression | 0 | 0.2% | 0.8% |
| Progression | 2–6 | 1% | 6% |
| Progression | 7–13 | 5% | 17% |
| Progression | 14–23 | 17% | 45% |
The progression score of 1 is not expected from the listed point allocations. The implementation handles this edge case conservatively in the lowest progression band to prevent an erroneous assignment to the highest band.
Important applicability considerations
- The EORTC 2006 tables use the WHO 1973 grading system and were derived from patients in clinical trials.
- Risk estimates may not calibrate well to every contemporary treatment setting, including patients receiving intravesical BCG. The EAU guideline distinguishes the 2006 EORTC model from later EORTC and CUETO models for BCG-treated patients.
- Do not use this calculator as a substitute for current guideline-based NMIBC risk grouping, pathology review, or individualized clinical judgment.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.